Exogenous Ochronosis: Characterizing a Rare Disorder in Skin of Color

An Update on New and Existing Treatments for the Management of Melasma

Melasma is a chronic, acquired disorder of focal hypermelanosis that carries significant psychosocial impact and is challenging for both the patient and the treating practitioner to manage in the medium to long term. Multiple treatments have been explored, often in combination given the many aetiological factors involved in its pathogenesis. Therapeutic discoveries to treat melasma are a focal topic in the literature and include a range of modalities, with recent developments including updates on visible light photoprotection, non-hydroquinone depigmenting agents, oral tranexamic acid, chemical peels, and laser and energy-based device therapy for melasma. It is increasingly important yet challenging to remain up-to-date on the arsenal of treatments available for melasma to find an efficacious and well-tolerated option for our patients.

An update on the safety of hydroquinone

Hydroquinone has been used for years for multiple conditions, including melasma, post-inflammatory hyperpigmentation, dyschromia from photoaging, and solar lentigines. It is known to be a very effective lightening agent, but several concerns have been raised about this widely used agent. The recent U.S. ban on over-the-counter skin lightening products containing hydroquinone has prompted further questioning of the safety of this widely used agent. While there have been prior informative, large-scale reviews on the safety of hydroquinone, new findings have since been reported. Here, we provide an updated review of studies published in the past 15 years on hydroquinone safety.

Exogenous Ochronosis: Clinicopathological Correlation in Indian Patients and the Practical Applicability of the Dogliotti and Phillips Classification Systems

Exogenous ochronosis (EO) results as a complication of long-term usage of skin lightening creams containing hydroquinone or other bleaching agents. Duration of use and concentration of hydroquinone in the product are noted to be key factors that decide the occurrence of EO. With more cases being reported globally, current classification systems lack practical applicability and may not be adequate for detecting early cases. Dermoscopy and clinicopathological correlation are very important for early diagnosis of EO to avoid undue overuse of hydroquinone leading to further deterioration of pigmentation. We report a series of six patients in one year with EO with the minimum duration of use of hydroquinone being three months to the development of ochronosis. The most common strength of hydroquinone used was 2%, documented in 5/6 cases. Three out of six patients (50%) had discordant findings according to the Dogliotti classification, while four out of six patients (66.7%) had discordant findings according to the Phillips classification. Our findings suggest that EO can occur with a shorter duration of hydroquinone use, even at lower percentage strengths. We propose that it may be more useful to accept the clinical presentation supported by dermoscopic features as adequate actionable findings, consider all the histopathological stages as warning signs of ochronosis or impending ochronosis, and terminate the use of hydroquinone in such patients.